Pete Najarian Is Watching Medivation (MDVN)
Tags: Pete Najarian
CNBC Fast Money's Pete Najarian is thinking about Medivation, Inc. (NASDAQ: MDVN), a biotech company that is working on a new drug in a partnership with Pfizer (NYSE: PFE).
He said that MDVN has a drug that is in the third phase of research and its results are expected in March. The drug is called Dimebon and it may help patients with Alzheimer's disease and Huntington disease.
The second phase was really successful, but Pete Najarian is still careful because he knows that these kind of trades can either be a hit or a miss.
One way to make this trade is through Pfizer (PFE). Medivation (MDVN) fell 1.75% today and Pfizer (PFE) dropped 0.67%
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
